Understanding the possible role of endocannabinoid system in obesity

被引:22
|
作者
Behl, Tapan [1 ]
Chadha, Swati [1 ]
Sachdeva, Monika [2 ]
Sehgal, Aayush [1 ]
Kumar, Arun [1 ]
Dhruv [1 ]
Venkatachalam, Thangavel [3 ]
Hafeez, Abdul [4 ]
Aleya, Lotfi [5 ]
Arora, Sandeep [1 ]
Batiha, Gaber El-Saber [6 ]
Nijhawan, Priya [1 ]
Bungau, Simona [7 ]
机构
[1] Chitkara Univ, Chitkara Coll Pharm, Chandigarh, Punjab, India
[2] Fatima Coll Hlth Sci, Al Ain, U Arab Emirates
[3] JKKMMRF Coll Pharm, Tiruchengode, Tamil Nadu, India
[4] Glocal Univ, Glocal Sch Pharm, Saharanpur, Uttar Pradesh, India
[5] Bourgogne Franche Comte Univ, Chronoenvironm Lab, Besancon, France
[6] Damanhour Univ, Fac Vet Med, Dept Pharmacol & Therapeut, Damanhour, Egypt
[7] Univ Oradea, Fac Med & Pharm, Dept Pharm, Oradea, Romania
关键词
Obesity; Endocannabinoid system; Adipocyte; High fat diet; CB1; receptor; CB2; CANNABINOID RECEPTOR ANTAGONIST; CARDIOMETABOLIC RISK-FACTORS; FOOD-INTAKE; ENERGY-EXPENDITURE; CB1; RECEPTORS; BODY-WEIGHT; ANANDAMIDE; ACTIVATION; RIMONABANT; INCREASES;
D O I
10.1016/j.prostaglandins.2020.106520
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Background: Maintenance of weight is essential for sustenance, well-being and to endorse prolonged life. The prevalence of obesity is increasing at an alarming rate globally, due to modern lifestyle and dietary habits. Endocannabinoids are fatty acid derivatives and numerous studies are carried out which focuses and targets their relationship with obesity, via multiple signals which have been recently known for exerting crucial role in regulating energy balance. Purpose: This article aims at examining the prospects of endocannabinoids in obesity via directing the role of ECs in stimulating hunger. Result: In last few years, irregular stimulation of endocannabinoid system has been suggested as a chief element in the progression of obesity-associated metabolic complications. Certainly, this cascade system comprises of cannabinoid type1 and 2 receptors (CB1R and CB2R) along with their endogenous lipid ligands which are responsible for enhanced feeding behavior as well as lipid metabolism. Significantly, inhibiting CB1R activity might reduce metabolic abnormality linked with obesity. Conclusion: Conclusion withdrawn on the basis of supporting scientific data and evidences report that the blockade of cannabinoids can serve as a therapeutic potential for treatment of obesity. Future prospective aims at assessing molecular pathways which contributes towards ECS, elicited weight control and to evaluate how these mechanisms are presently relocated into the production of novel cannabinoid drugs exhibiting enriched care.
引用
收藏
页数:9
相关论文
共 50 条
  • [31] Activation of the peripheral endocannabinoid system in human obesity
    Engeli, S
    Böhnke, J
    Feldpausch, M
    Gorzelniak, K
    Janke, J
    Bátkai, S
    Pacher, P
    Harvey-White, J
    Luft, FC
    Sharma, AM
    Jordan, J
    DIABETES, 2005, 54 (10) : 2838 - 2843
  • [32] The endocannabinoid system in obesity and type 2 diabetes
    Di Marzo, V.
    DIABETOLOGIA, 2008, 51 (08) : 1356 - 1367
  • [33] The role of the endocannabinoid system in atherosclerosis
    Mach, F.
    Steffens, S.
    JOURNAL OF NEUROENDOCRINOLOGY, 2008, 20 : 53 - 57
  • [34] The endocannabinoid system in the brain of Carassius auratus and its possible role in the control of food intake
    Valenti, M
    Cottone, E
    Martinez, R
    De Pedro, N
    Rubio, M
    Viveros, MP
    Franzoni, MF
    Delgado, MJ
    Di Marzo, V
    JOURNAL OF NEUROCHEMISTRY, 2005, 95 (03) : 662 - 672
  • [35] The role of the endocannabinoid system in skeletal muscle and metabolic adaptations to exercise: potential implications for the treatment of obesity
    Heyman, E.
    Gamelin, F. -X.
    Aucouturier, J.
    Di Marzo, V.
    OBESITY REVIEWS, 2012, 13 (12) : 1110 - 1124
  • [36] Endocannabinoid system and its implications for obesity and cardiometabolic risk
    Nesto, Richard W.
    Mackie, Ken
    EUROPEAN HEART JOURNAL SUPPLEMENTS, 2008, 10 (0B) : B34 - B41
  • [37] The circulating and central endocannabinoid system in obesity and weight loss
    Mattelaer, Nele
    van der Schueren, Bart
    Van Oudenhove, Lukas
    Weltens, Nathalie
    Vangoitsenhoven, Roman
    INTERNATIONAL JOURNAL OF OBESITY, 2024, 48 (10) : 1363 - 1382
  • [38] THE ENDOCANNABINOID SYSTEM AS A TARGET TO DECREASE THE CARDIOMETABOLIC RISK AND OBESITY
    Vazquez Vigoa, Alfredo
    Cruz Alvarez, Nelida Maria
    Vazquez Cruz, Alfredo
    Mendez Rosabal, Annerys
    Soledad Fernandez-Alfonso, Maria
    CLINICA E INVESTIGACION EN ARTERIOSCLEROSIS, 2009, 21 (03): : 151 - 156
  • [39] The Endocannabinoid System: Pivotal Orchestrator of Obesity and Metabolic Disease
    Mazier, Wilfrid
    Saucisse, Nicolas
    Gatta-Cherifi, Blandine
    Cota, Daniela
    TRENDS IN ENDOCRINOLOGY AND METABOLISM, 2015, 26 (10): : 524 - 537
  • [40] Rimonabant: an antagonist drug of the endocannabinoid system for the treatment of obesity
    Leite, Carlos E.
    Mocelin, Clei A.
    Petersen, Guilherme O.
    Leal, Mirna B.
    Thiesen, Flavia V.
    PHARMACOLOGICAL REPORTS, 2009, 61 (02) : 217 - 224